Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists
- PMID: 17562074
- DOI: 10.1007/s00428-007-0424-5
Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists
Abstract
HER2 is an important tumour marker in breast cancer. However, there is controversy regarding which method reliably measures HER2 status. This study evaluates the concordance between HER2 gene amplification in invasive breast cancer determined by fluorescence in situ hybridisation (FISH) and a new silver enhanced in situ hybridisation (SISH) technique. Ninety-nine cases were analysed by direct-labelled manual FISH (PathVysion(R), Abbott/Vysis) and bright field automated SISH (INFORM(R), Ventana). For comparison, all specimens were stained by immunohistochemistry (Dako-HercepTesttrade mark and Ventana-PATHWAY(R)4B5). Evaluation was performed by five pathologists following the algorithms of the manufacturers and the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. Concordance was calculated and the value of kappa statistics estimated. Overall concordance between FISH and SISH was 96.0% (kappa = 0.754, 95%CI). Discrepancies were mostly seen in tumours with intra-tumoural heterogeneity of HER2 amplification. In conclusion, HER2 gene copy status can be reliably determined by SISH. The 96% concordance with FISH fulfils the ASCO/CAP requirement of greater than 95% concordance for amplified vs non-amplified cases. There was a low inter-observer variability in the interpretation of SISH, suggesting that SISH is equally reliable in determining HER2 amplification as FISH. Because SISH combines bright field microscopy with molecular analysis and full automation, it appears to be particularly suited for routine application in surgical pathology.
Similar articles
-
Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.Am J Surg Pathol. 2010 Jun;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231. Am J Surg Pathol. 2010. PMID: 20421783
-
Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.J Mol Diagn. 2008 Nov;10(6):527-36. doi: 10.2353/jmoldx.2008.080052. Epub 2008 Oct 2. J Mol Diagn. 2008. PMID: 18832456 Free PMC article.
-
Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374. Diagn Mol Pathol. 2009. PMID: 19430296
-
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.J Clin Pathol. 2010 Mar;63(3):210-9. doi: 10.1136/jcp.2009.062760. J Clin Pathol. 2010. PMID: 20203220 Free PMC article. Review.
-
Emerging technologies for assessing HER2 amplification.Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Am J Clin Pathol. 2009. PMID: 19762531 Review.
Cited by
-
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion.NPJ Breast Cancer. 2023 Mar 22;9(1):16. doi: 10.1038/s41523-023-00517-2. NPJ Breast Cancer. 2023. PMID: 36949047 Free PMC article.
-
Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma.Mol Clin Oncol. 2020 Nov;13(5):64. doi: 10.3892/mco.2020.2134. Epub 2020 Sep 11. Mol Clin Oncol. 2020. PMID: 32968485 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.Signal Transduct Target Ther. 2019 Sep 13;4:34. doi: 10.1038/s41392-019-0069-2. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 31637013 Free PMC article. Review.
-
Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions.BMC Cancer. 2019 Sep 3;19(1):834. doi: 10.1186/s12885-019-6035-0. BMC Cancer. 2019. PMID: 31477048 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous